COPD

In a poster presented at ERS, researchers find the complement and coagulation cascades pathway was up-regulated in response to airway presence of Moraxella genera that might suggest an activation of systemic innate immunity in response to Moraxella.

COVID-19 positive patients with COPD demonstrated a greater risk for hospitalization, ICU admission, and need for invasive mechanical ventilation compared with non-COPD patients.

Data suggests treatment with the palliative opioid does not affect PCO2 levels, suggesting it is safe in patients with moderate to severe COPD.

Tiotropium plus olodaterol is more effective for patients with COPD compared with LABA plus inhaled corticosteroids.

A new case study  assesses biopsy and autopsy tissues to characterize pathological patterns in suspected EVALI cases .

New findings suggest differing chronic lung diseases are associated with varying risk factors among COVID-19 patients.

The approval are based on a pair of recent phase 3 trials showing the safety and efficacy of budesonide/glycopyrrolate/formoterol fumarate.

Genomics, in combination with patient demographic risks, could help better inform clinicians of persons at risk for worsened chronic pulmonary burden.

Where do investigators go next with the 8000-plus COPD patient research?

In an era of triple therapy combinations, what might a tailored approach look like?

New findings from the 8000-plus patient ETHOS trial shows triple inhaler therapy siginificantly betters patient mortality and symptoms over 52 weeks versus dual therapy.

New findings from ATS show the residual effects of vaping-associated lung distress.

A discussion with a study author on promising new findings for the combination inhaler therapy.

Little is understood about the systemic markers of worsening COPD. Investigators have observed at least 3 novel pathways.

A new assessment shows risk reduction is even more significant among COPD patients who have smoked.

An assessment of FF/UMEC/VI in a single inhaler show its benefit in respiratory function among COPD patients at 24 weeks.

A new study shows consistent confidence and anxiety of self-care with the injectable biologic in patients with asthma.

An assessment of a combined pharmacologic and cognitive behavioral therapy program shows patients improve FEV1, FVC, and other metrics.

Despite being advised in clinical guidelines, fewer than 2% of COPD patients initiate pulmonary rehabilitation within 90 days of hospitalization.

California is home of the cities with the most unhealthy pollution levels, according to the newest annual report from the ALA.

ALA chief medical officer Al Rizzo, MD, discusses plans to kickstart vaccine research and public health preventive measures.

COPD patients with unnoticed OSA are at a greater risk of hospital readmission and even all-cause mortality.

Al Rizzo, MD, of the American Lung Association, discusses some of the biggest challenges and questions raised on lung health during the coronavirus pandemic.

How do e-cigarettes fit into the cardiovascular health paradigm? What more needs to be learned?

Breaking down the details of the E3 trial, and what more needs to be found in the follow-up.

New ACC findings show smokers given nicotine or non-nicotine e-cigarettes better in 12-week cessation than those just given counseling.

Geeta Nayyar, MD, MBA, discusses how hydroxychloroquine and chloroquine affect patients with arthritis and how it differs for those with coronavirus.

A study of 416 hospitalized patients indicates 19.7% suffered cardiac injury, which was also associated with increased ventilation and mortality.

New expanded analysis from the IMPACT trial shows FF/UMEC/VI's benefit versus dual inhaler therapies.

About 1 in every 20 adult Americans now reguarly uses vaping and e-cigarette products.